An Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Nonhematologic Malignancies

This study is an open-label, multicenter, Phase 1, dose escalation study of MLN4924 in adult
patients with nonhematologic malignancies. This study will be the first to administer MLN4924
in humans. The patient population will consist of adults with any form of nonhematologic
malignancy for which standard, curative, life prolonging, or palliative treatment does not
exist or is no longer effective.